HCAC reviews applications pertaining to pathogen co-infections with HIV, AIDS associated opportunist pathogens, and cancers associated with HIV infection and/or antiretroviral drug therapies. The applications can focus on all aspects of molecular, animal models and clinical studies.

This include studies on co-infections with other infectious diseases including TB, malaria and hepatitis, as well as studies with pathogens (viral, fungal, parasitic and bacterial) that cause opportunistic infections due to the HIV/AIDS induced immunocompromised situation. HCAC will also review applications that focus on AIDS associated cancers and non-associated cancers that are increasing in people living with chronic HIV infection and/or cART.

The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Membership Panel

The membership panel is a list of chartered members only.


  • Molecular, cellular, and immunological studies of pathogenesis of AIDS-associated opportunistic pathogens in the context of HIV/AIDS including viral, fungal, parasitic and bacterial pathogens.
  • Studies on pathogens studied under immunocompromised situations that specifically relate to AIDS.
  • Studies of HIV/AIDS-associated cancers (e.g. Kaposi, lymphoma and cervical) including studies of their causative viruses (e.g., KSHV, EBV and HPV) and studies in animal models of these malignancies
  • Studies on non-AIDS associated precancers and cancers that are virally associated (hepatitis, HPV) and non-virally associated (prostate, lung) in people living with chronic HIV infection and/or cART.
  • Immune checkpoint inhibition strategies and immune regulated therapeutics for HIV associated coinfections and cancers
  • Preclinical and clinical ramifications and development of therapeutic approaches for opportunistic infections. infectious diseases such as TB, malaria, and hepatitis, and HIV associated and non-associated malignancies in the context of HIV/AIDS.
  • Mechanisms predisposing the elderly and infants to HIV coinfections and HIV associated malignancies.